MVA-85A vaccine

recombinant modified vaccinia Ankara expressing antigen 85A · University of Oxford (Jenner Institute)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MVA-85A vaccine, covering 2007-01-29 to 2007-01-29. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously [Phase 1]

See pricing